Publications & Blog
How to Invest in AI to Improve Clinical Trials
In this blog, we take a look at some specific ways current and emerging AI technologies are poised to improve clinical trials – from processes to patient outcomes – and what to look for when choosing an AI partner or platform.
How to Invest in AI to Improve Clinical Trials
In this blog, we take a look at some specific ways current and emerging AI technologies are poised to improve clinical trials – from processes to patient outcomes – and what to look for when choosing an AI partner or platform.
%20(1).png)
Generative AI & Drug Development – What You Need To Know
Researchers are beginning to look at the utility of generative AI in drug development for specific ways this particular type of machine learning technology might help streamline, improve, or otherwise accelerate the development of new drugs. Here’s what you need to know about generative AI and drug development.
Generative AI & Drug Development – What You Need To Know
Researchers are beginning to look at the utility of generative AI in drug development for specific ways this particular type of machine learning technology might help streamline, improve, or otherwise accelerate the development of new drugs. Here’s what you need to know about generative AI and drug development.
Integrating AI/ML Models for Patient Stratification Leveraging Omics Dataset and Clinical Biomarkers from COVID-19 Patients
In this manuscript, we demonstrate the recent advances and predictive accuracies in AI- and ML-based patient stratification modeling linking omics and clinical biomarker datasets, focusing on COVID-19 patients.
Integrating AI/ML Models for Patient Stratification Leveraging Omics Dataset and Clinical Biomarkers from COVID-19 Patients
In this manuscript, we demonstrate the recent advances and predictive accuracies in AI- and ML-based patient stratification modeling linking omics and clinical biomarker datasets, focusing on COVID-19 patients.
Dose Optimization: How to Get it Right
At the heart of dose optimization is a mandate to safeguard the health of study participants. From unwanted side effects to reduced efficacy and toxicity, the pharmacological effect of administered doses for any potential drug candidate must always be carefully vetted for safety and efficacy. Let’s take a closer look at dose optimization – what it is and how to get it right.
Dose Optimization: How to Get it Right
At the heart of dose optimization is a mandate to safeguard the health of study participants. From unwanted side effects to reduced efficacy and toxicity, the pharmacological effect of administered doses for any potential drug candidate must always be carefully vetted for safety and efficacy. Let’s take a closer look at dose optimization – what it is and how to get it right.
.png)
Introducing AtlasGEN™ Novel Drug Designer
AtlasGEN Novel Drug Designer efficiently identifies new molecules based on favorable chemical properties and simultaneously evaluates them for clinical safety and effectiveness based on biology using VeriSIM Life’s groundbreaking Translational Index™ technology.
Iterative ranking of target engaging hits by their Translational Index values reduces the time and cost associated with other computational hit discovery approaches, while compressing the hit-to-lead refinement and optimization process by pre-validating hits for translatability. This unique integration dramatically reduces the number of compounds to evaluate in subsequent experimental research.
The ability to generate target engaging compound hits depends largely on the size of the molecular search library. The AtlasGEN search space is supported by more than 1 trillion compounds. Generative AI and deep learning techniques deliver unprecedented discovery capability.
AtlasGEN accurately predicts protein-lygand binding affinity by combining geometric conformer analysis with machine learning based on experimental data 72% more efficiently than molecular docking-based approaches.
